Altimmune (Nasdaq: ALT) presented new analyses at the EASL International Liver Congress™ demonstrating the effectiveness of the MASH Resolution Index (MASHResInd) in predicting MASH resolution for patients treated with pemvidutide. The analysis showed impressive response rates, with 69.2%, 92.3%, and 90.9% of subjects receiving 1.2mg, 1.8mg, and 2.4mg of pemvidutide respectively achieving MASHResInd responses, compared to just 22.2% in the placebo group. The MASHResInd algorithm, developed by Dr. Rohit Loomba, combines multiple non-invasive tests to predict MASH resolution on biopsy. These results suggest a high probability of achieving MASH resolution in Altimmune's ongoing IMPACT Phase 2b Trial, with the company expecting to report results this quarter.
りくくん
>>221
グッド
引用
↓
Altimmune (Nasdaq: ALT) presented new analyses at the EASL International Liver Congress™ demonstrating the effectiveness of the MASH Resolution Index (MASHResInd) in predicting MASH resolution for patients treated with pemvidutide. The analysis showed impressive response rates, with 69.2%, 92.3%, and 90.9% of subjects receiving 1.2mg, 1.8mg, and 2.4mg of pemvidutide respectively achieving MASHResInd responses, compared to just 22.2% in the placebo group. The MASHResInd algorithm, developed by Dr. Rohit Loomba, combines multiple non-invasive tests to predict MASH resolution on biopsy. These results suggest a high probability of achieving MASH resolution in Altimmune's ongoing IMPACT Phase 2b Trial, with the company expecting to report results this quarter.
投資の参考になりましたか？